Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 167

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Bactericidal versus bacteriostatic antibacterials: clinical significance, differences and synergistic potential in clinical practice

Ishak, Angela, Mazonakis, Nikolaos, Spernovasilis, Nikolaos, Akinosoglou, Karolina, Tsioutis, Constantinos · 2025 · Journal of Antimicrobial Chemotherapy

Abstract

Antibacterial activity can be classified as either bactericidal or bacteriostatic, using methods such as the MBC/MIC ratio and time–kill curves. However, such categorization has proven challenging in clinical practice, as these definitions only apply under specific laboratory conditions, which may differ from clinical settings. Several factors, such as the specific bacteria or infectious medium, can affect the action of antibiotics, with many antibacterials exerting both activities. These definitions have also led to the belief that bactericidal antibacterials are superior to bacteriostatic, especially in more severe cases, such as endocarditis, neutropenia and bacteraemia. Additionally, current dogma dictates against the combination of bactericidal and bacteriostatic antibacterials in clinical practice, due to potential antagonism. This review aimed to assess the differences in antibacterial activity of bactericidal and bacteriostatic antibacterials based on in vitro and in vivo studies and examine their antagonistic or synergistic effects. Our findings show that specific bacteriostatic agents, such as linezolid and tigecycline, are clinically non-inferior to bactericidals in multiple infections, including pneumonia, intra-abdominal infections, and skin and soft tissue infections. Studies also support using several bacteriostatic agents as salvage therapies in severe infections, such as neutropenic fever and endocarditis. Additionally, not all combinations of bacteriostatic and bactericidal agents appear to be antagonistic, with many combinations, such as linezolid and rifampicin, already being used. The findings should be interpreted with caution, as most evidence is from observational studies and there is a need for randomized controlled trials to assess their effectiveness and combinations, especially within the context of rising antimicrobial resistance.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jac/dkae380

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 115

  1. Pankey, 2004, Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of gram-positive bacterial infections, Clin Infect Dis, 38, 864, 10.1086/381972 · DOI · Paper page
  2. Wald-Dickler, 2018, Busting the myth of ‘static vs cidal’: a systemic literature review, Clin Infect Dis, 66, 1470, 10.1093/cid/cix1127 · DOI · Paper page
  3. Prasetyoputri, 2019, The eagle effect and antibiotic-induced persistence: two sides of the same coin?, Trends Microbiol, 27, 339, 10.1016/j.tim.2018.10.007 · DOI · Paper page
  4. Mogana, 2020, Antibacterial activities of the extracts, fractions and isolated compounds from Canarium patentinervium Miq. against bacterial clinical isolates, BMC Complement Med Ther, 20, 55, 10.1186/s12906-020-2837-5 · DOI · Paper page
  5. Levison, 2009, Pharmacokinetics and pharmacodynamics of antibacterial agents, Infect Dis Clin North Am, 23, 791, 10.1016/j.idc.2009.06.008 · DOI · Paper page
  6. Baquero, 2021, Proximate and ultimate causes of the bactericidal action of antibiotics, Nat Rev Microbiol, 19, 123, 10.1038/s41579-020-00443-1 · DOI · Paper page
  7. Craig, 1993, Pharmacodynamics of antimicrobial agents as a basis for determining dosage regimens, Eur J Clin Microbiol Infect Dis, 12, S6, 10.1007/BF02389870 · doi:10.1007/bf02389870
  8. Ambrose, 2007, Antimicrobial resistance: pharmacokinetics-pharmacodynamics of antimicrobial therapy: it’s not just for mice anymore, Clin Infect Dis, 44, 79, 10.1086/510079 · DOI · Paper page
  9. Steigbigel, 2019, Static vs cidal antibiotics, Clin Infect Dis, 68, 351, 10.1093/cid/ciy645 · DOI
  10. Zahedi Bialvaei, 2017, Linezolid: a promising option in the treatment of gram-positives, J Antimicrob Chemother, 72, 354, 10.1093/jac/dkw450 · DOI · Paper page
  11. Watkins, 2012, An evidence-based review of linezolid for the treatment of methicillin-resistant Staphylococcus aureus (MRSA): place in therapy, Core Evid, 7, 131, 10.2147/CE.S33430 · DOI
  12. Clemett, 2000, Linezolid, Drugs, 59, 815, 10.2165/00003495-200059040-00007 · doi:10.2165/00003495-200059040-00007
  13. Scott, 2019, Eravacycline: a review in complicated intra-abdominal infections, Drugs, 79, 315, 10.1007/s40265-019-01067-3 · DOI
  14. Silva, 2011, Bacteriostatic versus bactericidal activity of ciprofloxacin in Escherichia coli assessed by flow cytometry using a novel far-red dye, J Antibiot, 64, 321, 10.1038/ja.2011.5 · DOI
  15. Rahal, 1979, Bactericidal and bacteriostatic action of chloramphenicol against meningeal pathogens, Antimicrob Agents Chemother, 16, 13, 10.1128/AAC.16.1.13 · doi:10.1128/aac.16.1.13
  16. Stein, 2006, Tigecycline: a critical analysis, Clin Infect Dis, 43, 518, 10.1086/505494 · DOI · Paper page
  17. Greer, 2006, Tigecycline (tygacil): the first in the glycylcycline class of antibiotics, Baylor Univ Med Cent), 19, 155, 10.1080/08998280.2006.11928154 · doi:10.1080/08998280.2006.11928154
  18. Johansen, 2000, Antagonism between penicillin and erythromycin against Streptococcus pneumoniae in vitro and in vivo, J Antimicrob Chemother, 46, 973, 10.1093/jac/46.6.973 · DOI
  19. Daschner, 1976, Combination of bacteriostatic and bactericidal drugs: lack of significant in vitro antagonism between penicillin, cephalothin, and rolitetracycline, Antimicrob Agents Chemother, 10, 802, 10.1128/AAC.10.5.802 · DOI
  20. Weeks, 1981, Antagonism of ampicillin and chloramphenicol for meningeal isolates of group B streptococci, Antimicrob Agents Chemother, 20, 281, 10.1128/AAC.20.3.281 · doi:10.1128/aac.20.3.281
  21. Singh, 2017, Suppressive drug combinations and their potential to combat antibiotic resistance, J Antibiot, 70, 1033, 10.1038/ja.2017.102 · DOI
  22. Allison, 1992, Effect of polysaccharide interactions on antibiotic susceptibility of Pseudomonas aeruginosa, J Appl Bacteriol, 73, 484, 10.1111/j.1365-2672.1992.tb05009.x · DOI
  23. Chevereau, 2015, Systematic discovery of drug interaction mechanisms, Mol Syst Biol, 11, 807, 10.15252/msb.20156098 · DOI
  24. Ocampo, 2014, Antagonism between bacteriostatic and bactericidal antibiotics is prevalent, Antimicrob Agents Chemother, 58, 4573, 10.1128/AAC.02463-14 · DOI · Paper page
  25. Iversen, 2019, Partial oral versus intravenous antibiotic treatment of endocarditis, N Engl J Med, 380, 415, 10.1056/NEJMoa1808312 · DOI · Paper page
  26. Jacqueline, 2003, In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time-kill curve methods, J Antimicrob Chemother, 51, 857, 10.1093/jac/dkg160 · DOI
  27. Valderrama, 2020, Synergy of linezolid with several antimicrobial agents against linezolid-methicillin-resistant staphylococcal strains, Antibiotics, 9, 496, 10.3390/antibiotics9080496 · DOI
  28. Jiang, 2021, Synergistic combination of linezolid and fosfomycin closing each other’s mutant selection window to prevent enterococcal resistance, Front Microbiol, 11, 605962, 10.3389/fmicb.2020.605962 · DOI
  29. Leijtens, 2017, Clindamycin-rifampin combination therapy for staphylococcal periprosthetic joint infections: a retrospective observational study, BMC Infect Dis, 17, 321, 10.1186/s12879-017-2429-2 · doi:10.1186/s12879-017-2429-2
  30. Bonnaire, 2021, Clindamycin combination treatment for the treatment of bone and joint infections caused by clindamycin-susceptible, erythromycin-resistant Staphylococcus spp, Diagn Microbiol Infect Dis, 99, 115225, 10.1016/j.diagmicrobio.2020.115225 · doi:10.1016/j.diagmicrobio.2020.115225
  31. Ochi, 2018, The effect of oral clindamycin and rifampicin combination therapy in patients with hidradenitis suppurativa in Singapore, Clin Cosmet Investig Dermatol, 11, 37, 10.2147/CCID.S136730 · doi:10.2147/ccid.s136730
  32. Albur, 2012, Bactericidal activity of multiple combinations of tigecycline and colistin against NDM-1-producing Enterobacteriaceae, Antimicrob Agents Chemother, 56, 3441, 10.1128/AAC.05682-11 · doi:10.1128/aac.05682-11
  33. Zhou, 2020, Colistin combined with tigecycline: a promising alternative strategy to combat Escherichia coli harboring blaNDM-5 and mcr-1, Front Microbiol, 10, 2957, 10.3389/fmicb.2019.02957 · DOI
  34. Sato, 2021, Effects of colistin and tigecycline on multidrug-resistant Acinetobacter baumannii biofilms: advantages and disadvantages of their combination, Sci Rep, 11, 11700, 10.1038/s41598-021-90732-3 · DOI
  35. Chusri, 2019, Adjunctive therapy of intravenous colistin to intravenous tigecycline for adult patients with non-bacteremic post-surgical intra-abdominal infection due to carbapenem-resistant Acinetobacter baumannii, J Infect Chemother, 25, 681, 10.1016/j.jiac.2019.03.017 · DOI
  36. Amat, 2018, The combined use of tigecycline with high-dose colistin might not be associated with higher survival in critically ill patients with bacteraemia due to carbapenem-resistant Acinetobacter baumannii, Clin Microbiol Infect, 24, 630, 10.1016/j.cmi.2017.09.016 · DOI
  37. Hespanhol, 2020, Pneumonia mortality, comorbidities matter?, Pulmonology, 26, 123, 10.1016/j.pulmoe.2019.10.003 · doi:10.1016/j.pulmoe.2019.10.003
  38. Pletz, 2020, International perspective on the new 2019 American Thoracic Society/Infectious Diseases Society of America Community-Acquired Pneumonia guideline: a critical appraisal by a global expert panel, Chest, 158, 1912, 10.1016/j.chest.2020.07.089 · DOI
  39. Kalil, 2016, Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society, Clin Infect Dis, 63, e61, 10.1093/cid/ciw504 · DOI · Paper page
  40. Bohte, 1995, Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community-acquired pneumonia, Eur J Clin Microbiol Infect Dis, 14, 182, 10.1007/BF02310353 · DOI
  41. Genné, 1997, Clarithromycin versus amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia, Eur J Clin Microbiol Infect Dis, 16, 783, 10.1007/BF01700406 · doi:10.1007/bf01700406
  42. Kuzman, 2005, Clinical efficacy and safety of a short regimen of azithromycin sequential therapy vs standard cefuroxime sequential therapy in the treatment of community-acquired pneumonia: an international, randomized, open-label study, J Chemother, 17, 636, 10.1179/joc.2005.17.6.636 · DOI
  43. Dartois, 2008, Tigecycline versus levofloxacin for the treatment of community-acquired pneumonia: European experience, J Chemother, 20, 28, 10.1179/joc.2008.20.Supplement-1.28 · DOI
  44. Tanaseanu, 2008, Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia, Diagn Microbiol Infect Dis, 61, 329, 10.1016/j.diagmicrobio.2008.04.009 · DOI
  45. Bergallo, 2009, Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin, Diagn Microbiol Infect Dis, 63, 52, 10.1016/j.diagmicrobio.2008.09.001 · DOI
  46. Mokabberi, 2010, Doxycycline vs. levofloxacin in the treatment of community-acquired pneumonia, J Clin Pharm Ther, 35, 195, 10.1111/j.1365-2710.2009.01073.x · DOI
  47. Stets, 2019, Omadacycline for community-acquired bacterial pneumonia, N Engl J Med, 380, 517, 10.1056/NEJMoa1800201 · DOI · Paper page
  48. Rodriguez, 2023, Omadacycline in the treatment of community-acquired bacterial pneumonia in patients with comorbidities: a post-hoc analysis of the phase 3 OPTIC trial, Front Med (Lausanne), 10, 1225710, 10.3389/fmed.2023.1225710 · doi:10.3389/fmed.2023.1225710
  49. Ramirez, 2021, Efficacy of omadacycline versus moxifloxacin in the treatment of community-acquired bacterial pneumonia by disease severity: results from the OPTIC study, Open Forum Infect Dis, 8, ofab135, 10.1093/ofid/ofab135 · doi:10.1093/ofid/ofab135
  50. Kadowaki, 2005, Reappraisal of clindamycin IV monotherapy for treatment of mild-to-moderate aspiration pneumonia in elderly patients, Chest, 127, 1276, 10.1378/chest.127.4.1276 · doi:10.1378/chest.127.4.1276
  51. Freire, 2010, Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia, Diagn Microbiol Infect Dis, 68, 140, 10.1016/j.diagmicrobio.2010.05.012 · DOI · Paper page
  52. Ramirez, 2013, Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia, Antimicrob Agents Chemother, 57, 1756, 10.1128/AAC.01232-12 · DOI · Paper page
  53. Wang, 2015, Linezolid versus vancomycin for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a systematic review employing meta-analysis, Eur J Clin Pharmacol, 71, 107, 10.1007/s00228-014-1775-x · DOI
  54. Kato, 2021, Meta-analysis of vancomycin versus linezolid in pneumonia with proven methicillin-resistant Staphylococcus aureus, J Glob Antimicrob Resist, 24, 98, 10.1016/j.jgar.2020.12.009 · DOI
  55. Nemeth, 2015, Bacteriostatic versus bactericidal antibiotics for patients with serious bacterial infections: systematic review and meta-analysis, J Antimicrob Chemother, 70, 382, 10.1093/jac/dku379 · DOI · Paper page
  56. Saleem, 2022, Mortality and clinical cure rates for pneumonia: a systematic review, meta-analysis, and trial sequential analysis of randomized control trials comparing bactericidal and bacteriostatic antibiotic treatments, Clin Microbiol Infect, 28, 936, 10.1016/j.cmi.2021.12.021 · DOI
  57. Eckmann, 2013, Efficacy of tigecycline for the treatment of complicated intra-abdominal infections in real-life clinical practice from five European observational studies, J Antimicrob Chemother, 68, ii25, 10.1093/jac/dkt142 · DOI
  58. Oliva, 2005, A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections, BMC Infect Dis, 5, 88, 10.1186/1471-2334-5-88 · DOI
  59. Towfigh, 2010, A multicentre, open-label, randomized comparative study of tigecycline versus ceftriaxone sodium plus metronidazole for the treatment of hospitalized subjects with complicated intra-abdominal infections, Clin Microbiol Infect, 16, 1274, 10.1111/j.1469-0691.2010.03122.x · DOI
  60. Qvist, 2012, Efficacy of tigecycline versus ceftriaxone plus metronidazole for the treatment of complicated intra-abdominal infections: results from a randomized, controlled trial, Surg Infect (Larchmt), 13, 102, 10.1089/sur.2011.048 · DOI
  61. Alosaimy, 2022, Clinical outcomes of eravacycline in patients treated predominately for carbapenem-resistant Acinetobacter baumannii, Microbiol Spectr, 10, e0047922, 10.1128/spectrum.00479-22 · DOI
  62. Solomkin, 2017, Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) trial: a randomized clinical trial, JAMA Surg, 152, 224, 10.1001/jamasurg.2016.4237 · DOI · Paper page
  63. Solomkin, 2019, IGNITE4: results of a phase 3, randomized, multicenter, prospective trial of eravacycline vs meropenem in the treatment of complicated intraabdominal infections, Clin Infect Dis, 69, 921, 10.1093/cid/ciy1029 · DOI · Paper page
  64. Meng, 2022, The efficacy and safety of eravacycline compared with current clinically common antibiotics in the treatment of adults with complicated intra-abdominal infections: a Bayesian network meta-analysis, Front Med (Lausanne), 9, 935343, 10.3389/fmed.2022.935343 · DOI
  65. Moffarah, 2016, Skin and soft tissue infections, Microbiol Spectr, 4, 4.4.14, 10.1128/microbiolspec.DMIH2-0014-2015 · DOI
  66. Eckmann, 2010, Treatment of complicated skin and soft-tissue infections caused by resistant bacteria: value of linezolid, tigecycline, daptomycin and vancomycin, Eur J Med Res, 15, 554, 10.1186/2047-783X-15-12-554 · DOI
  67. Bartoszko, 2018, Antibiotic therapy for skin and soft tissue infections: a protocol for a systematic review and network meta-analysis, Syst Rev, 7, 138, 10.1186/s13643-018-0804-8 · DOI
  68. Stevens, 2014, Executive summary: practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America, Clin Infect Dis, 59, 147, 10.1093/cid/ciu444 · DOI · Paper page
  69. Itani, 2010, Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus, Am J Surg, 199, 804, 10.1016/j.amjsurg.2009.08.045 · DOI
  70. Wilcox, 2009, Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study, Clin Infect Dis, 48, 203, 10.1086/595686 · DOI · Paper page
  71. Weigelt, 2005, Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections, Antimicrob Agents Chemother, 49, 2260, 10.1128/AAC.49.6.2260-2266.2005 · DOI · Paper page
  72. Chuang, 2011, Efficacy and safety of tigecycline monotherapy compared with vancomycin-aztreonam in the treatment of complicated skin and skin structure infections in patients from India and Taiwan, J Microbiol Immunol Infect, 44, 116, 10.1016/j.jmii.2010.04.002 · DOI
  73. Sacchidanand, 2005, Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: results from a phase 3, randomized, double-blind trial, Int J Infect Dis, 9, 251, 10.1016/j.ijid.2005.05.003 · DOI
  74. Cenizal, 2007, Prospective randomized trial of empiric therapy with trimethoprim-sulfamethoxazole or doxycycline for outpatient skin and soft tissue infections in an area of high prevalence of methicillin-resistant Staphylococcus aureus, Antimicrob Agents Chemother, 51, 2628, 10.1128/AAC.00206-07 · DOI
  75. Harbarth, 2015, Randomized non-inferiority trial to compare trimethoprim/sulfamethoxazole plus rifampicin versus linezolid for the treatment of MRSA infection, J Antimicrob Chemother, 70, 264, 10.1093/jac/dku352 · DOI
  76. Jauregui, 2005, Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections, Clin Infect Dis, 41, 1407, 10.1086/497271 · DOI · Paper page
  77. Cepeda, 2004, Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study, J Antimicrob Chemother, 53, 345, 10.1093/jac/dkh048 · DOI
  78. Papadopoulos, 2009, Efficacy and tolerability of linezolid in chronic osteomyelitis and prosthetic joint infections: a case-control study, J Chemother, 21, 165, 10.1179/joc.2009.21.2.165 · doi:10.1179/joc.2009.21.2.165
  79. Zhou, 2023, Comparative study of linezolid and vancomycin regimens in one-stage surgery for treating limb traumatic osteomyelitis caused by methicillin-resistant Staphylococcus aureus, Pol J Microbiol, 72, 239, 10.33073/pjm-2023-024 · DOI
  80. Sawada, 2019, Linezolid versus daptomycin treatment for periprosthetic joint infections: a retrospective cohort study, J Orthop Surg Res, 14, 334, 10.1186/s13018-019-1375-7 · doi:10.1186/s13018-019-1375-7
  81. Benavent, 2021, Long-term use of tedizolid in osteoarticular infections: benefits among oxazolidinone drugs, Antibiotics, 10, 53, 10.3390/antibiotics10010053 · doi:10.3390/antibiotics10010053
  82. Frenck, 2000, Azithromycin versus ceftriaxone for the treatment of uncomplicated typhoid fever in children, Clin Infect Dis, 31, 1134, 10.1086/317450 · DOI
  83. Begum, 2014, Comparison between azithromycin and cefixime in the treatment of typhoid fever in children, Mymensingh Med J, 23, 441
  84. Girgis, 1999, Azithromycin versus ciprofloxacin for treatment of uncomplicated typhoid fever in a randomized trial in Egypt that included patients with multidrug resistance, Antimicrob Agents Chemother, 43, 1441, 10.1128/AAC.43.6.1441 · DOI
  85. Acharya, 1995, Treatment of typhoid fever: randomized trial of a three-day course of ceftriaxone versus a fourteen-day course of chloramphenicol, Am J Trop Med Hyg, 52, 162, 10.4269/ajtmh.1995.52.162 · DOI
  86. Arjyal, 2011, Gatifloxacin versus chloramphenicol for uncomplicated enteric fever: an open-label, randomised, controlled trial, Lancet Infect Dis, 11, 445, 10.1016/S1473-3099(11)70089-5 · DOI
  87. Marchello, 2020, A systematic review on antimicrobial resistance among salmonella typhi worldwide, Am J Trop Med Hyg, 103, 2518, 10.4269/ajtmh.20-0258 · DOI
  88. Sebbane, 2021, Antibiotic therapy of plague: a review, Biomolecules, 11, 724, 10.3390/biom11050724 · DOI
  89. Mwengee, 2006, Treatment of plague with gentamicin or doxycycline in a randomized clinical trial in Tanzania, Clin Infect Dis, 42, 614, 10.1086/500137 · DOI
  90. Rafailidis, 2009, Linezolid for patients with neutropenia: are bacteriostatic agents appropriate?, Expert Rev Anti Infect Ther, 7, 415, 10.1586/eri.09.11 · DOI
  91. Jaksic, 2006, Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer, Clin Infect Dis, 42, 597, 10.1086/500139 · DOI · Paper page
  92. Bucaneve, 2014, Results of a multicenter, controlled, randomized clinical trial evaluating the combination of piperacillin/tazobactam and tigecycline in high-risk hematologic patients with cancer with febrile neutropenia, J Clin Oncol, 32, 1463, 10.1200/JCO.2013.51.6963 · DOI
  93. Zhou, 2018, Salvage tigecycline in high risk febrile neutropenic patients with hematological malignancies: a prospective multicenter study, Leuk Lymphoma, 59, 2679, 10.1080/10428194.2018.1436173 · doi:10.1080/10428194.2018.1436173
  94. Modemann, 2022, Efficacy of tigecycline as salvage therapy in multidrug-resistant febrile neutropenia in patients with acute leukemia—a single center analysis, Antibiotics, 11, 128, 10.3390/antibiotics11020128 · doi:10.3390/antibiotics11020128
  95. Biscarini, 2021, A case of Corynebacterium striatum endocarditis successfully treated with an early switch to oral antimicrobial therapy, Infez Med, 29, 138
  96. Imoto, 2021, Corynebacterium jeikeium-induced infective endocarditis and perivalvular abscess diagnosed by 16S ribosomal RNA sequence analysis: a case report, J Infect Chemother, 27, 906, 10.1016/j.jiac.2021.01.005 · doi:10.1016/j.jiac.2021.01.005
  97. Yazaki, 2018, A successful salvage therapy with daptomycin and linezolid for right-sided infective endocarditis and septic pulmonary embolism caused by methicillin-resistant Staphylococcus aureus, J Infect Chemother, 24, 845, 10.1016/j.jiac.2018.02.006 · DOI
  98. Amiyangoda, 2017, A complicated prosthetic valve endocarditis due to methicillin resistant staphylococci treated with linezolid and ciprofloxacin: a case report, BMC Res Notes, 10, 580, 10.1186/s13104-017-2907-z · DOI
  99. Hill, 2006, Infective endocarditis treated with linezolid: case report and literature review, Eur J Clin Microbiol Infect Dis, 25, 202, 10.1007/s10096-006-0111-5 · DOI
  100. Muñoz, 2021, Linezolid for infective endocarditis: a structured approach based on a national database experience, Medicine (Baltimore), 100, e27597, 10.1097/MD.0000000000027597 · DOI
  101. Lauridsen, 2012, Linezolid as rescue treatment for left-sided infective endocarditis: an observational, retrospective, multicenter study, Eur J Clin Microbiol Infect Dis, 31, 2567, 10.1007/s10096-012-1597-7 · DOI
  102. Balli, 2014, Systematic review and meta-analysis of linezolid versus daptomycin for treatment of vancomycin-resistant enterococcal bacteremia, Antimicrob Agents Chemother, 58, 734, 10.1128/AAC.01289-13 · DOI · Paper page
  103. Chuang, 2014, Daptomycin versus linezolid for treatment of vancomycin-resistant enterococcal bacteremia: systematic review and meta-analysis, BMC Infect Dis, 14, 687, 10.1186/s12879-014-0687-9 · DOI
  104. Seaton, 2015, Evaluation of effectiveness and safety of high-dose daptomycin: results from patients included in the European Cubicin® Outcomes Registry and Experience, Adv Ther, 32, 1192, 10.1007/s12325-015-0267-4 · DOI
  105. Zhao, 2016, Similar efficacy and safety of daptomycin versus linezolid for treatment of vancomycin-resistant enterococcal bloodstream infections: a meta-analysis, Int J Antimicrob Agents, 48, 231, 10.1016/j.ijantimicag.2016.06.010 · DOI
  106. Shi, 2020, Efficacy and safety of daptomycin versus linezolid treatment in patients with vancomycin-resistant enterococcal bacteraemia: an updated systematic review and meta-analysis, J Glob Antimicrob Resist, 21, 235, 10.1016/j.jgar.2019.10.008 · DOI
  107. Kawasuji, 2023, Effectiveness and safety of linezolid versus vancomycin, teicoplanin, or daptomycin against methicillin-resistant Staphylococcus aureus bacteremia: a systematic review and meta-analysis, Antibiotics (Basel), 12, 697, 10.3390/antibiotics12040697 · DOI
  108. Willekens, 2019, Early oral switch to linezolid for low-risk patients with Staphylococcus aureus bloodstream infections: a propensity-matched cohort study, Clin Infect Dis, 69, 381, 10.1093/cid/ciy916 · DOI
  109. Duke, 2003, Chloramphenicol or ceftriaxone, or both, as treatment for meningitis in developing countries?, Arch Dis Child, 88, 536, 10.1136/adc.88.6.536 · DOI
  110. Myrianthefs, 2006, Serum and cerebrospinal fluid concentrations of linezolid in neurosurgical patients, Antimicrob Agents Chemother, 50, 3971, 10.1128/AAC.00051-06 · doi:10.1128/aac.00051-06
  111. Tsona, 2010, Linezolid penetration into cerebrospinal fluid and brain tissue, J Chemother, 22, 17, 10.1179/joc.2010.22.1.17 · DOI
  112. Sipahi, 2011, Linezolid in the treatment of methicillin-resistant staphylococcal post-neurosurgical meningitis: a series of 17 cases, Scand J Infect Dis, 43, 757, 10.3109/00365548.2011.585177 · DOI
  113. Faella, 2006, Combined treatment with ceftriaxone and linezolid of pneumococcal meningitis: a case series including penicillin-resistant strains, Clin Microbiol Infect, 12, 391, 10.1111/j.1469-0691.2006.01352.x · DOI
  114. Sipahi, 2013, Vancomycin versus linezolid in the treatment of methicillin-resistant Staphylococcus aureus meningitis, Surg Infect (Larchmt), 14, 357, 10.1089/sur.2012.091 · DOI
  115. Hussain A, 2001, Successful treatment of vancomycin-resistant Enterococcus faecium meningitis with linezolid: case report and literature review, Scand J Infect Dis, 33, 375, 10.1080/003655401750174048 · doi:10.1080/003655401750174048

Cited by

See all 167

Metadata

Authors
Ishak, A., Mazonakis, N., Spernovasilis, N., Akinosoglou, K., & Tsioutis, C.
Venue
Journal of Antimicrobial Chemotherapy
Published
2024-10-29
Volume
80
Issue
1
Pages
1-17
ISSN
  • 0305-7453
  • 1460-2091
Cited by
167
References
1
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bactericidal versus bacteriostatic antibacterials: clinical significance, differences and synergistic potential in clinical practice. https://app.cochat.ai/papers/10.1093/jac/dkae380
The paper
Ishak, A., Mazonakis, N., Spernovasilis, N., Akinosoglou, K., & Tsioutis, C. (2025). Bactericidal versus bacteriostatic antibacterials: clinical significance, differences and synergistic potential in clinical practice. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae380

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.